23 hours Ago By Defense World Staff
Renaissance Technologies LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 89.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
The institutional investor owned 26,110 shares of the biopharmaceutical company’s stock after selling 229,170 shares during the quarter. Renaissance Technologies LLC’s holdings in Halozyme Therapeutics were worth $1,248,000 as of its most recent filing with the Securities and Exchange Commission. Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business.
2Xideas AG boosted its stake in shares of Halozyme Therapeutics by 24.1% in the fourth quarter. 2Xideas AG now owns 379,240 shares of the biopharmaceutical company’s stock valued at $18,131,000 after buying an additional 73,653 shares in the last quarter.
Aviva PLC boosted its position in shares of Halozyme Therapeutics by 39.3% during the 4th quarter. Aviva PLC now owns 137,413 shares of the biopharmaceutical company’s stock worth $6,570,000 after purchasing an additional 38,765 shares in the last quarter.
Prudential PLC grew its stake in shares of Halozyme Therapeutics by 3.2% during the 4th quarter. Prudential PLC now owns 58,075 shares of the biopharmaceutical company’s stock worth $2,777,000 after purchasing an additional 1,813 shares during the period.
Bryce Point Capital LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $607,000. Finally, Huntington National Bank lifted its stake in shares of Halozyme Therapeutics by 68.2% in the fourth quarter.
Huntington National Bank now owns 3,180 shares of the biopharmaceutical company’s stock valued at $152,000 after purchasing an additional 1,289 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.
Halozyme Therapeutics Stock PerformanceShares of NASDAQ HALO opened at $60.82 on Wednesday. The company has a 50-day simple moving average of $60.
63 and a 200-day simple moving average of $55.24. The company has a debt-to-equity ratio of 4.
14, a current ratio of 7.80 and a quick ratio of 9.15.
The company has a market cap of $7.51 billion, a PE ratio of 17.73, a price-to-earnings-growth ratio of 0.
42 and a beta of 1.32. Halozyme Therapeutics, Inc.
has a 12 month low of $37.97 and a 12 month high of $66.00.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.
17 by $0.02. Halozyme Therapeutics had a net margin of 43.
74% and a return on equity of 157.78%. The firm had revenue of $298.
01 million during the quarter, compared to analysts’ expectations of $285.74 million. On average, equities analysts anticipate that Halozyme Therapeutics, Inc.
will post 4.73 earnings per share for the current year. Insiders Place Their BetsIn related news, SVP Michael J.
Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.
16. Following the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68.
This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Also, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.
00. Following the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30.
This represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
In the last ninety days, insiders have sold 26,697 shares of company stock valued at $1,558,052. Insiders own 2.40% of the company’s stock.
Wall Street Analysts Forecast GrowthA number of equities research analysts have recently issued reports on HALO shares. HC Wainwright reiterated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday, April 25th.
Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th.
JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $55.00 to $58.
00 and gave the company a “neutral” rating in a report on Monday, April 21st. Piper Sandler lifted their price target on Halozyme Therapeutics from $52.00 to $53.
00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, Benchmark reissued a “buy” rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th.
Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $62.89.
View Our Latest Research Report on HALOHalozyme Therapeutics Company Profile (Free Report)Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.Further ReadingFive stocks we like better than Halozyme TherapeuticsWhat is the S&P/TSX Index?Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetLow PE Growth Stocks: Unlocking Investment OpportunitiesCoca-Cola Company Stock Can Bubble to New Highs This YearFind and Profitably Trade Stocks at 52-Week Lows3 Stocks Lifting 2025 Guidance Despite Market JittersWant to see what other hedge funds are holding HALO? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report)..
